Two-year treatment with oral contraceptives in hyperprolactinemic patients

Giovanna Testa, Walter Vegetti, Tiziano Motta, Federica Alagna, Diana Bianchedi, Clelia Carlucci, Massimiliano Bianchi, Fabio Parazzini, Pier Giorgio Crosignani

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 ± 29.4 μg/mL, range 4.2-97.1 μg/mL vs 56.3 ± 31.5 μg/mL, range 23.5-144 μg/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalContraception
Volume58
Issue number2
DOIs
Publication statusPublished - Aug 1998

Fingerprint

Oral Contraceptives
Hyperprolactinemia
Prolactin
Therapeutics
Prospective Studies
Serum

Keywords

  • Hyperprolactinemia
  • Microadenoma
  • Oral contraception
  • Pituitary
  • Prospective study

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Cite this

Testa, G., Vegetti, W., Motta, T., Alagna, F., Bianchedi, D., Carlucci, C., ... Crosignani, P. G. (1998). Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception, 58(2), 69-73. https://doi.org/10.1016/S0010-7824(98)00069-9

Two-year treatment with oral contraceptives in hyperprolactinemic patients. / Testa, Giovanna; Vegetti, Walter; Motta, Tiziano; Alagna, Federica; Bianchedi, Diana; Carlucci, Clelia; Bianchi, Massimiliano; Parazzini, Fabio; Crosignani, Pier Giorgio.

In: Contraception, Vol. 58, No. 2, 08.1998, p. 69-73.

Research output: Contribution to journalArticle

Testa, G, Vegetti, W, Motta, T, Alagna, F, Bianchedi, D, Carlucci, C, Bianchi, M, Parazzini, F & Crosignani, PG 1998, 'Two-year treatment with oral contraceptives in hyperprolactinemic patients', Contraception, vol. 58, no. 2, pp. 69-73. https://doi.org/10.1016/S0010-7824(98)00069-9
Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception. 1998 Aug;58(2):69-73. https://doi.org/10.1016/S0010-7824(98)00069-9
Testa, Giovanna ; Vegetti, Walter ; Motta, Tiziano ; Alagna, Federica ; Bianchedi, Diana ; Carlucci, Clelia ; Bianchi, Massimiliano ; Parazzini, Fabio ; Crosignani, Pier Giorgio. / Two-year treatment with oral contraceptives in hyperprolactinemic patients. In: Contraception. 1998 ; Vol. 58, No. 2. pp. 69-73.
@article{c904dd5a50ce4122af28c6ccac080ff6,
title = "Two-year treatment with oral contraceptives in hyperprolactinemic patients",
abstract = "The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 ± 29.4 μg/mL, range 4.2-97.1 μg/mL vs 56.3 ± 31.5 μg/mL, range 23.5-144 μg/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients.",
keywords = "Hyperprolactinemia, Microadenoma, Oral contraception, Pituitary, Prospective study",
author = "Giovanna Testa and Walter Vegetti and Tiziano Motta and Federica Alagna and Diana Bianchedi and Clelia Carlucci and Massimiliano Bianchi and Fabio Parazzini and Crosignani, {Pier Giorgio}",
year = "1998",
month = "8",
doi = "10.1016/S0010-7824(98)00069-9",
language = "English",
volume = "58",
pages = "69--73",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Two-year treatment with oral contraceptives in hyperprolactinemic patients

AU - Testa, Giovanna

AU - Vegetti, Walter

AU - Motta, Tiziano

AU - Alagna, Federica

AU - Bianchedi, Diana

AU - Carlucci, Clelia

AU - Bianchi, Massimiliano

AU - Parazzini, Fabio

AU - Crosignani, Pier Giorgio

PY - 1998/8

Y1 - 1998/8

N2 - The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 ± 29.4 μg/mL, range 4.2-97.1 μg/mL vs 56.3 ± 31.5 μg/mL, range 23.5-144 μg/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients.

AB - The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 ± 29.4 μg/mL, range 4.2-97.1 μg/mL vs 56.3 ± 31.5 μg/mL, range 23.5-144 μg/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients.

KW - Hyperprolactinemia

KW - Microadenoma

KW - Oral contraception

KW - Pituitary

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=0032144854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032144854&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(98)00069-9

DO - 10.1016/S0010-7824(98)00069-9

M3 - Article

C2 - 9773260

AN - SCOPUS:0032144854

VL - 58

SP - 69

EP - 73

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 2

ER -